Literature DB >> 20403681

DNA gyrase and topoisomerase IV are dual targets of zabofloxacin in Streptococcus pneumoniae.

Hee Soo Park, Sung Ji Jung, Jin-Hwan Kwak, Dong-Rack Choi, Eung-Chil Choi.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20403681     DOI: 10.1016/j.ijantimicag.2010.02.022

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


× No keyword cloud information.
  5 in total

Review 1.  Pharmacotherapy of Lower Respiratory Tract Infections in Elderly-Focused on Antibiotics.

Authors:  Yang Liu; Yan Zhang; Wanyu Zhao; Xiaolei Liu; Fengjuan Hu; Birong Dong
Journal:  Front Pharmacol       Date:  2019-10-31       Impact factor: 5.810

Review 2.  Emerging Treatment Options for Infections by Multidrug-Resistant Gram-Positive Microorganisms.

Authors:  Despoina Koulenti; Elena Xu; Andrew Song; Isaac Yin Sum Mok; Drosos E Karageorgopoulos; Apostolos Armaganidis; Sotirios Tsiodras; Jeffrey Lipman
Journal:  Microorganisms       Date:  2020-01-30

3.  Zabofloxacin versus moxifloxacin in patients with COPD exacerbation: a multicenter, double-blind, double-dummy, randomized, controlled, Phase III, non-inferiority trial.

Authors:  Chin Kook Rhee; Jung Hyun Chang; Eu Gene Choi; Hyun Kuk Kim; Yong-Soo Kwon; Sun Young Kyung; Ji-Hyun Lee; Myung Jae Park; Kwang Ha Yoo; Yeon Mok Oh
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2015-10-22

4.  In Vitro and In Vivo Activity of Zabofloxacin and Other Fluoroquinolones Against MRSA Isolates from A University Hospital in Egypt.

Authors:  Nelly M Mohamed; Azza S Zakaria; Eva A Edward; Amany Abdel-Bary
Journal:  Pol J Microbiol       Date:  2019

Review 5.  Mutational Diversity in the Quinolone Resistance-Determining Regions of Type-II Topoisomerases of Salmonella Serovars.

Authors:  Aqsa Shaheen; Anam Tariq; Mazhar Iqbal; Osman Mirza; Abdul Haque; Thomas Walz; Moazur Rahman
Journal:  Antibiotics (Basel)       Date:  2021-11-26
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.